CompletedNCT01725308
Quetiapine Compared With Placebo for Bipolar Depression
About this title
A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
Read the official source — NCT01725308Medication studyAges 20–64JapanBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Aichi and 97 more locationsSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: February 7, 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 431
- Sponsor
- Astellas Pharma Inc
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Japan
- Age range
- From 20 Years to 64 Years
- Official registry ID
- NCT01725308
- Official title
Show the full official title
Phase II/III Study of FK949E: Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes
Get this study by email
Recruitment & locations
CompletedAichi · Akita · Chiba
23 more locations
- Fukuoka
- Fukushima
- Gifu
- Gunma
- Hiroshima
- Hokkaido
- Ibaraki
- Kagawa
- Kanagawa
- Kumamoto
- Kyoto
- Miyagi
- Nagano
- Nara
- Okayama
- Okinawa
- Osaka
- Ōita
- Shizuoka
- Tokushima
- Tokyo
- Tottori
- Toyama
Questions about this study
Who is behind this study?
The study sponsor is Astellas Pharma Inc, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including FK949E and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
